1. Home
  2. USIO vs SCYX Comparison

USIO vs SCYX Comparison

Compare USIO & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • USIO
  • SCYX
  • Stock Information
  • Founded
  • USIO 1998
  • SCYX 1999
  • Country
  • USIO United States
  • SCYX United States
  • Employees
  • USIO N/A
  • SCYX N/A
  • Industry
  • USIO Investment Bankers/Brokers/Service
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • USIO Finance
  • SCYX Health Care
  • Exchange
  • USIO Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • USIO 36.6M
  • SCYX 40.9M
  • IPO Year
  • USIO N/A
  • SCYX 2014
  • Fundamental
  • Price
  • USIO $1.52
  • SCYX $0.90
  • Analyst Decision
  • USIO Strong Buy
  • SCYX
  • Analyst Count
  • USIO 2
  • SCYX 0
  • Target Price
  • USIO $5.00
  • SCYX N/A
  • AVG Volume (30 Days)
  • USIO 120.6K
  • SCYX 94.5K
  • Earning Date
  • USIO 05-14-2025
  • SCYX 05-07-2025
  • Dividend Yield
  • USIO N/A
  • SCYX N/A
  • EPS Growth
  • USIO N/A
  • SCYX N/A
  • EPS
  • USIO 0.12
  • SCYX N/A
  • Revenue
  • USIO $82,931,840.00
  • SCYX $3,746,000.00
  • Revenue This Year
  • USIO $16.14
  • SCYX $460.12
  • Revenue Next Year
  • USIO $13.51
  • SCYX $253.87
  • P/E Ratio
  • USIO $12.67
  • SCYX N/A
  • Revenue Growth
  • USIO N/A
  • SCYX N/A
  • 52 Week Low
  • USIO $1.24
  • SCYX $0.73
  • 52 Week High
  • USIO $2.92
  • SCYX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • USIO 52.89
  • SCYX 45.97
  • Support Level
  • USIO $1.24
  • SCYX $0.89
  • Resistance Level
  • USIO $1.57
  • SCYX $0.99
  • Average True Range (ATR)
  • USIO 0.11
  • SCYX 0.08
  • MACD
  • USIO 0.02
  • SCYX 0.01
  • Stochastic Oscillator
  • USIO 84.85
  • SCYX 64.71

About USIO Usio Inc.

Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: